CVS Caremark study notes lack of adherence to cholesterol-lowering medications
When it comes to nonadherence of prescription medications, it is often senior citizens who are the subject of the discussion, but the findings of the recent CVS Caremark study point to those under the age of 45. The findings are not only alarming but also important as they further demonstrate the need for healthcare reform and for retail pharmacy to rise to the challenge and be part of the solution.
Unless steps are taken to address the problem of non-adherence, these younger adults will further weigh on an already broken healthcare system because they face an increased risk for developing heart disease, which, in the end, will increase their healthcare costs. As it stands, non-adherence currently costs the United States an estimated $177 billion a year.
CVS Caremark has been vocal on its desire to be on the front lines of health care and clearly recognizes that it is in an ideal position to help with the healthcare solution. In fact, much of its focus has been on adherence programs, disease management and wellness programs.
As described in the article, CVS Caremark has developed the Proactive Pharmacy Care approach, which engages patients earlier with education and personalized outreach to improve adherence. According to CVS Caremark, its Adherence to Care program has been shown to help increase adherence to high cholesterol therapies with those members under 45 years of age who participate in the program experiencing a medication possession ratio increase of more than 9%.
Safeway adds two to board of directors
PLEASANTON, Calif. Safeway on Monday named Arun Sarin and Michael Shannon to the company’s board of directors. The company’s board of directors will expand from 10 to 12 members with these new appointments, the company stated.
“We are fortunate to have individuals with these credentials joining the board,” stated Safeway chairman, president and CEO Steve Burd. “[Sarin] and [Shannon] have each run substantial businesses, and their experience will be valuable to our board.”
Sarin has worked in the telecommunications industry for the majority of his career. Most recently, he was the CEO of Vodafone Group, one of the world’s largest mobile phone companies by revenue. Sarin has served on numerous boards including Gap, Charles Schwab and Cisco Systems. He recently retired from being a non-executive director of the Court of the Bank of England.
Shannon founded KSL Capital Partners in 2004 and its predecessor, KSL Recreation Corporation, in 1992, serving as its president and CEO. KSL Capital Partners is a U.S. private equity firm dedicated to investments in travel and leisure businesses. Shannon also founded and became CEO of KSL Resorts in 2004, following the sale of KSL Recreation. During his tenure as CEO, KSL Recreation grew to become one of the largest independent owners and operators of resorts. From 1986 to 1992, Shannon served as president and CEO of Vail Associates, owner of the Vail and Beaver Creek resorts in Colorado. He currently serves on the board of ING Direct, the Vail Valley Foundation, the United States Ski and Snowboard Association and Eisenhower Memorial Hospital.
IRI discusses health care during recession in new report
CHICAGO Information Resources Inc. on Thursday released a report, “The Changing Landscape of Healthcare and the American Consumer,” outlining the forward impact the current recession will have on how Americans research, purchase and use health care.
“Health care is costly, and people are rethinking how they take care of themselves in order to conserve funds,” Thom Blischok, president, consulting and innovation, IRI, wrote in the opening of the report. “Instead of sticking with their tried-and-true healthcare options, consumers are aggressively seeking affordable solutions for health and wellness, both in terms of how they obtain care and in the healthcare products they choose.”
And while Americans are changing how they choose health care, the Food and Drug Administration is “flexing its regulatory muscles again.” And while the new FDA activism is expected to make medicines and supplements safer, it also has the potential to add significant costs overall — including added costs in drug development as well as added costs to keep those medicines already approved on store or pharmacy shelves.